Health Care & Life Sciences » Biotechnology | Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
387.00
229.00
250.00
154.00
1,605.00
30,336
SG&A Expense
34,193.00
75,752.00
118,692.00
110,169.00
131,430.00
209,484
EBIT
33,950.00
75,846.00
119,076.00
110,732.00
130,538.00
179,883
Non Operating Income/Expense
-
28.00
2.00
10.00
81.00
33
Pretax Income
33,947.00
75,777.00
118,181.00
109,438.00
128,921.00
178,381
Income Tax
-
-
-
139.00
63.00
26
Consolidated Net Income
33,947.00
75,777.00
118,181.00
109,577.00
128,984.00
178,407
Net Income
33,947.00
75,777.00
118,181.00
109,577.00
128,984.00
178,407
Net Income After Extraordinaries
33,947.00
75,777.00
118,181.00
109,577.00
128,984.00
178,407
Net Income Available to Common
33,947.00
75,777.00
118,181.00
109,577.00
128,984.00
178,407
EPS (Basic)
5.59
2.43
3.32
2.92
2.81
3.14
Basic Shares Outstanding
6,067.70
31,135.70
35,619.50
37,523.10
45,899.80
56,799.70
EPS (Diluted)
5.59
2.43
3.32
2.92
2.81
3.14
Diluted Shares Outstanding
6,067.70
31,135.70
35,619.50
37,523.10
45,899.80
56,799.70
EBITDA
33,806.00
75,523.00
118,442.00
110,015.00
129,825.00
179,148
Non-Operating Interest Income
3.00
97.00
897.00
1,284.00
1,698.00
4,028

About Karyopharm Therapeutics

View Profile
Address
85 Wells Avenue
Newton Massachusetts 02459
United States
Employees -
Website http://www.karyopharm.com
Updated 07/08/2019
Karyopharm Therapeutics, Inc. is a clinical-stage pharmaceutical company, The engages in the discovery, development, and commercialization of drugs to treat cancer and other major diseases. The company intends to initiate a pivotal randomized Phase 3 study of selinexor in combination with bortezomib (Velcade) and low-dose dexamethasone (BOSTON) in patients with multiple myeloma. Karyopharm Therapeutics was founded by Joseph Araujo, Ronald A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.